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The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase involved in the
regulation of growth in many animal cells, including cancer cells. Phosphorylation of specific
tyrosine residues within the cytoplasmic domain of EGFR is part of the initial activation
process that occurs upon ligand binding, and these phosphotyrosine residues subsequently
serve as docking sites for intracellular signaling molecules. To study the phosphorylation on
each individual site, EGFR generated from a human epidermoid carcinoma cell line (A431)
was analyzed by mass spectrometry. Liquid chromatography combined with tandem mass
spectrometry (LC/MS/MS) was used to identify the tryptic phosphopeptides and their sites of
phosphorylation (Y992, Y1045, Y1068, Y1086, S1142, Y1148, and Y1173). Ion intensities for the
phosphorylated and unphosphorylated tryptic peptides containing the sites of phosphoryla-
tion were measured, and the intensity ratios were used to assess the degree of phosphorylation
at each site. Ligand concentrations were varied for epidermal growth factor (EGF) and
transforming growth factor alpha (TGF) as stimuli, and all of the EGFR tyrosine sites were
consequently found to exhibit increased levels of phosphorylation, although at different rates
and to different extents. Phosphorylation of Y992 appeared to plateau at lower concentrations
of ligand, whereas the other sites continued to have increased phosphorylation throughout a
wide range of concentrations. Only small differences could be detected between the EGF and
the TGF-induced EGFR phosphorylation. Pretreatment of A431 cells with a small molecule
EGFR inhibitor nearly eliminated the ligand-induced phosphorylation on all of the sites except
for Y992 and Y1068. (J Am Soc Mass Spectrom 2003, 14, 1022–1031) © 2003 American Society
for Mass Spectrometry
Mature EGFR is a type I membrane glycoproteinwith 1186 amino acids consisting of an extra-cellular domain for ligand binding, a single
membrane-spanning section, and a cytoplasmic protein
kinase domain [1]. Like other proteins in the receptor
tyrosine kinase family, EGFR play an important role in
regulating cell functions such as proliferation, migra-
tion and differentiation. EGFR, also known as ErbB1 or
HER1, is a member of the ErbB family of receptors, and
can be activated by several different ligands—EGF,
TGF, amphiregulin (AR), betacellulin (BTC), heparin-
binding EGF (HB-EGF), and epiregulin (EPR) [2]. Al-
though BTC, HB-EGF, and EPR can bind to both EGFR
and ErbB4, there is no experimental evidence suggest-
ing that EGF, TGF, and AR bind to receptors other
than EGFR. Upon ligand binding, members of ErbB
family form both homo- and hetero-dimers [3]. Dimer-
ization activates the intrinsic protein tyrosine kinase
activities of the receptors, leading to phosphorylation of
specific tyrosine residues within the cytoplasmic do-
main [4–8]. These tyrosine phosphorylation sites serve
as docking sites for intracellular signaling proteins
containing Src homology 2 (SH2) or phosphotyrosine
binding (PTB) domains [9] and provide a crucial con-
nection between the external stimuli and internal signal
transduction pathways.
A number of human tumors express high levels of
EGFR and its ligands, and increased expression of
EGFR has sometimes been found to correlate with poor
prognosis for cancer patients [10]. Hence, EGFR has
become a target for a number of oncology therapeutics
under development. Recently, it has been reported that
a small molecule EGFR-specific kinase inhibitor may
affect a subset of patients, but evidence of significant
responses in the treated patient population as a whole
was less significant [11]. Since a key linkage between
the external stimuli and internal signaling is tyrosine
phosphorylation, a better understanding of the quanti-
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tative changes among the different phosphorylation
sites in response to ligands and inhibitors may provide
a better understanding of the mechanism of action of
EGFR inhibition. Towards this end, a mass spectromet-
ric study of EGFR phosphorylation was initiated.
Over a period of 15 years (1984–1999) of extensive
study, six tyrosine residues from the carboxyl terminus
of EGFR, distal from the tyrosine kinase domain (resi-
due 688–955), were reported to be phosphorylated in
vivo upon ligand stimulation. These include tyrosine
residue 1068, 1148, 1173 [4], 1086 [5, 6], 992 [7], and 1045
[8]. These sites were mapped using in vivo 32P-labeling
of truncated or point-mutated EGFR. During the past
two decades, immunodetection of in vivo tyrosine
phosphorylated EGFR after ligand activation has been
the primary tool for researchers to monitor the extent of
total phosphorylation within intact EGFR. However, a
drawback of this approach is that it measures accumu-
lative changes in overall phosphorylation, rather than
dynamic changes at specific sites.
Methods involving radiological detection of 32P la-
beled proteins, such as 2-D phosphopeptide analysis
and solid phase Edman sequencing [12] are particularly
useful for accounting for all of the 32P originally incor-
porated into a protein. Nevertheless, for many labora-
tories the use of high levels of 32P for in vivo labeling is
not feasible, and non-radioactive methods are the only
option. Immunodetection is often used; however, for
monitoring specific sites this typically requires prior
development of antibodies. Furthermore, stoichiometry
is difficult to determine with this method. DNA mu-
tagenesis has also been used to study phosphorylation;
however, this tends to be mostly a hypothesis-driven
approach rather than an unbiased screen.
Since the introduction of electrospray and matrix-
assisted laser desorption ionization [13, 14], mass spec-
trometry has emerged as the preferred non-radioactive
method for characterizing protein phosphorylation.
However, in a given sample it is usually very difficult to
find the few spectra that represent phosphopeptides
amongst all of the rest of the data. Towards this end
various methods have been developed for the enrich-
ment and identification of phosphopeptides [15–17].
Other means of locating and identifying phosphopep-
tides include comparisons with phosphatase treated
controls [18], comparisons between positive and nega-
tive MALDI spectra [19], the use of specialized mass
spectrometer scans [20, 21] or analyzing large numbers
of MS/MS spectra of peptides generated by digesting a
sample with several different proteases [22].
Most of the aforementioned mass spectrometric
methods provide qualitative information, and there
have been relatively few mass spectrometry methods
described for phosphate quantitation. Isotope dilution
methods could be used for this purpose and would
likely be quite accurate; however, these methods re-
quire the synthesis of isotopically labeled peptides [23]
or the use of isotope enriched cell culture media [24]. A
few researchers have suggested that a comparison of
mass spectrometric signals of phosphorylated peptides
with internal controls (i.e., an unmodified peptide de-
rived from the same protein) can provide adequate
quantitation. The difference between these reported
methods seems to be in the choice of internal standard,
and whether it should be the corresponding unphos-
phorylated peptide [25, 26] or a peptide derived from
the same protein that does not contain any modifica-
tions [27]. Ideally, one would want the internal stan-
dard to have physical and chemical properties that are
most similar to that of the phosphorylated peptide to be
quantitated. Assuming that phosphorylation does not
influence proteolytic cleavage, the corresponding un-
phosphorylated peptide would be the best candidate.
We chose to use the latter method to monitor gross
changes in phosphorylation, and are subsequently us-
ing isotope labeled synthetic phosphopeptides [23] to
verify the quantitation. In addition, pairs of unlabeled
synthetic phosphorylated and unphosphorylated pep-
tides were synthesized in order to gauge the effect of
phosphorylation on ionization efficiency for individual
peptides [27, 28].
A431 cells, a human epidermoid carcinoma cell line
in which EGFR is over-expressed [29], were treated
under various conditions, and EGFR was immunopre-
cipitated with an EGFR antibody. Each of the immuno-
precipitates was subjected to one dimensional poly-
acrylamide gel electrophoresis, and the EGFR bands
were excised and an in-gel trypsin digest was per-
formed. Six previously known phosphorylation sites on
EGFR were found in 5 tryptic peptides, as well as an
additional unknown serine phosphorylation site. The
site-specific changes in phosphorylation were moni-
tored using LC-MS. EGFR phosphorylation following
EGF or TGF stimulation was compared, and the effect
of an EGFR kinase inhibitor on ligand-induced phos-
phorylation was also examined.
Experimental
Cell Culture
Cultures of the human epidermoid carcinoma cell line
A-431 [30] (American Type Culture Collection, Manas-
sas, VA) were grown in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum plus anti-
biotics until 80% confluence was reached. Cell culture
continued for an additional 16 h in the absence of
serum. Cells were either untreated or treated with
ligands at the various concentrations (see the Results
section) for 20 min at 37 °C. Approximately 1  10e7
cells were used in each treatment. For experiments
involving EGFR inhibition, cells were pretreated with
AG1478 [4-(3-chloroanilino)-6,7-dimethoxyquinazoline]
(LC Laboratories, Woburn, MA) 20 min prior to addi-
tion of 100 ng/ml of either EGF or TGF (Upstate
Biotechnology, Waltham, MA).
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EGFR Immunoprecipitation
After ligand treatment, cells were washed two times
with ice-cold 150 mM NaCl, 100 mM sodium phosphate
pH 7.2 (PBS) and the cells were lysed in PBS containing
1% Triton X-100, 1mM NaF, 1 mM -glycerol-phos-
phate, 1 mM sodium orthovanadate, and a protease
inhibitor cocktail (Roche Diagnostics Corporation, Indi-
anapolis, IN). Cell lysates were precleared with Protein
A-Sepharose and then immunoprecipitated with 4
ug/ml anti-EGFR clone LA22 (Upstate Biotechnology).
Protein Gel separation, Reduction, Alkylation,
and Digestion
Following immunoprecipitation, EGFR was isolated
using SDS-PAGE under reducing conditions using
Tris/glycine 4–20% gradient precast Novex gels (In-
vitrogen, Carlsbad, CA). Protein bands were stained
using Colloidal Blue (Invitrogen). Gel bands were man-
ually excised and the gel pieces were processed using
an automated protein digestion station (Genomic Solu-
tions, Ann Arbor, MI) that performed the tasks of
reduction and alkylation of cysteines, tryptic digestion
(Promega, Madison, WI), and extraction of the peptides.
Mass Spectrometry
Mass spectrometry analysis of tryptic peptides was
performed on a Micromass QTOF 1 instrument
(Manchester, United Kingdom). Peptides were se-
quenced by on-line microcapillary liquid chromatogra-
phy-electrospray ionization-tandem mass spectrometry
(LC/MS/MS) operated in a data-dependent mode, and
phosphopeptides were identified using the Mascot pro-
gram [31]. The capillary column was made from a piece
of 50-m i.d. fused silica line with an internal frit (New
Objective, Cambridge, MA) that was packed with YMC
ODS-AQ resin (Waters, Milford, MA). The LC gradient
(0–75% solvent B in 60 min, solvent A  0.1% formic
acid, 0.001% heptafluorobutyric acid (HFBA), and 5%
acetonitrile; solvent B  80% acetonitrile) was devel-
oped using an Eldex Micropro syringe pump (Napa,
CA) operating at 8 l/min. A preinjector splitter cut the
flow to approximately 250 nl/min. The effluent of the
column was directed into an Upchurch (Oak Harbor,
WA) micro-tee containing a platinum electrode and a
New Objective uncoated fused silica tip (360 m o.d., 20
m i.d., pulled to a 10 m opening). Ion intensity data
were obtained from mass spectra generated using mi-
crocapillary liquid chromatography-electrospray ion-
ization-mass spectrometry (LC/MS).
Peptide Synthesis
Solid phase peptide synthesis was performed on an
Applied Biosystems model 433A synthesizer using
Fmoc chemistry with reagents and Fmoc-amino acids
from Applied Biosystems (Foster City, CA). Fmoc-
Tyr(PO3H2)-OH was from NovaBiochem (San Diego,
CA) and stable-isotope labeled Fmoc-[15N]Val-OH and
Fmoc-[15N]Ala-OH were from Bachem (Torance, CA).
Peptides were cleaved from the resin and deblocked
using reagent K (trifluoroacetic acid, ethanedithiol and
thioanisole). Resin was removed by filtration. Peptides
were precipitated in cold methyl butyl ether followed
by multiple washes with cold diethyl ether to remove
deblocking reagents. Peptide purification was carried
out on a semi preparative HPLC column, C18 10  250
mm from Vydac (Hesperia, CA), using aqueous/aceto-
nitrile gradients in 0.1% trifluoroacetic acid. Fractions of
the major peak were collected, checked for purity by
analytical HPLC and MALDI-MS. The pure fractions
were pooled and lyophilized for storage.
Results and Discussion
Identification of EGFR Phosphorylation Sites
In order to monitor changes in ligand-induced EGFR
phosphorylation, it was first necessary to find and
characterize peptides that contained the various phos-
phorylation sites. In-gel tryptic digestion of immuno-
precipitated EGFR was performed, and the tryptic
peptides were analyzed by data-dependent LC/MS/
MS. To increase the likelihood of collecting MS/MS
spectra of lower abundance precursor ions, consecutive
LC/MS/MS acquisitions were performed over narrow
precursor mass ranges (e.g., 100 u wide precursor
survey scans) [32]. In a few cases, precursor ion selec-
tion was used in order to obtain CID spectra to verify
the structure of specific phosphopeptides (see below).
All of the previously reported tyrosine phosphorylation
sites (Table 1) were found, and their sequences were
confirmed by tandem mass spectrometry (see below). In
addition to tyrosine phosphorylation, a serine phos-
phorylation site (S1142) was identified.
Two of the tyrosine phosphorylation sites, Y1045 and
Y1068, are located in the same tryptic peptide and the
two monophosphorylated forms cannot be distin-
guished by mass alone. However, these two peptides
could be separated by HPLC, and the MS/MS spectra
clearly demonstrated their structural differences (Fig-
ure 1). Whereas the other sites had previously been
identified on the basis of phosphopeptide mapping
[4–7], ligand-induced phosphorylation at Y1045 was
Table 1. EFGR tryptic peptides containing phosphorylation
sites
MWa Sequence
3606.57 ALMDEEDMDDVVDADEY(992)LIPQQGFFSSPSTSR
3397.61 Y(1045)SSDPTGALTEDSIDDTFLPVPEY(1068)INQSVPK
2398.23 RPAGSVQNPVY(1086)HNQPLNPAPSR
2235.02 GSHQIS(1142)LDNPDY(1148)QQDFFPK
1209.56 GSTAENAEY(1173)LR
aMonoisotopic molecular weights are calculated for the unphosphory-
lated peptides.
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implicated using site-directed mutagenesis data, and
inhibitory effects of a synthetic phosphopeptide [8]. In
contrast, the data reported here (Figure 1b) provides
structural evidence that Y1045 is a ligand-induced
phosphorylation site. The b4 ion at m/z 533.128 indicates
the presence of phosphate within the first three residues
(YSS). The absence of an ion resulting from -elimina-
tion of phosphate from the precursor ion, a fragmenta-
tion that is typical for peptides containing phosphory-
lated serine or threonine, suggests that the phosphate is
located on tyrosine. The presence of a phosphorylation
site at the N-terminus of this tryptic peptide (Y1045)
could conceivably result in reduced efficiency of pro-
teolytic cleavage; however, no evidence of a larger
partial tryptic phosphopeptide encompassing this site
was found. Another peptide containing two phosphor-
ylation sites was found containing Y1148 and S1142,
and the two monophosphorylated forms could be sep-
arated by HPLC and their structures were verified by
MS/MS (Figure 2). For both peptides (Figure 1 and
Figure 2) the doubly phosphorylated peptide ions were
of very low abundance and their ion intensities could
not be accurately measured.
Assessment of Quantitation Methods
for Determining Changes in Ligand-Induced
EGFR Phosphorylation
To analyze the changes in phosphorylation sites in a
quantitative manner, the immunopurified EGFR has to
accurately reflect the state of the protein in vivo. The
Figure 1. Tandem mass spectra of monophosphorylated EGFR tryptic peptides encompassing
positions 1045-1075. (a) The earlier eluting peptide was identified as
YSSDPTGALTEDSIDDTFLPVPEY*INQSVPK (Y* represents phosphorylation at Y1068). (b) The later
eluting peptide was identified as Y*SSDPTGALTEDSIDDTFLPVPEYINQSVPK (Y* represents phos-
phorylation at Y1045). The ion labeled b4 is absent from the spectrum shown in panel (a). Ion
assignments use the Biemann nomenclature [37].
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specific antibody that was used (LA22) [33] recognizes
the extra cellular domain, and should therefore not be
selective for or against different phosphorylation states
of EGFR. Comparison of the Coomassie-stained EGFR
bands from either unstimulated or EGF-stimulated cells
showed that approximately the same amount of protein
was recovered for each immunoprecipitation, despite
the large differences found in the corresponding West-
ern blots probed using an anti-phosphotyrosine anti-
body (data not shown).
Having characterized the observed tryptic EGFR
phosphopeptides using LC/MS/MS (e.g., Figure 1 and
Figure 2), a simpler analysis employing a single stage of
mass spectrometry (i.e., LC/MS) is capable of monitor-
ing changes in these phosphorylation sites under dif-
ferent stimulation conditions. Peptides in these LC/MS
acquisitions are identified based on the m/z value (with
error less than 20 ppm), and by their chromatographic
retention time. One of the difficulties in using mass
spectrometry for quantitative analysis is that the fluc-
tuation in instrument response needs to be normalized
before different samples can be reliably compared. Ions
derived from other EGFR tryptic peptides can serve this
purpose, and we chose to use the ion intensity of the
corresponding unphosphorylated tryptic peptide, since
these are closely matched in terms of amino acid
composition, mass, and HPLC elution time. Thus, sim-
ple ratios of the ion intensities of the phosphopeptides
versus the corresponding unphosphorylated peptides
were used to assess changes in phosphorylation for
specific sites. The addition of phosphate to a peptide
generally causes it to elute slightly earlier, depending
on the peptide size. For example, the short 11 residue
phospho-Y1173 peptide elutes nearly two min ahead of
Figure 2. Tandem mass spectra of monophosphorylated EGFR tryptic peptides encompassing
positions 1137–1154. (a) The earlier eluting peptide was identified as GSHQISLDNPDY*QQDFFPK (Y*
represents phosphorylation at Y1148). (b) The later eluting peptide was identified as
GSHQIS*LDNPDYQQDFFPK (S* represents phosphorylation at S1142). Some of the larger unlabeled
peaks are b-type ions that had suffered a loss of phosphate via a gas phase beta-elimination reaction.
Ion assignments use the Biemann nomenclature [37].
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the unphosphorylated peptide (Figure 3b, left), whereas
most of the others behaved more like what is shown in
the inset of Figure 3a. Usually the ions of interest were
not contaminated by coeluting molecules with similar
m/z values, and quantitative data analysis in these cases
was relatively simple (Figure 3a). However there were
times when the data analysis was more complicated.
For example, an unrelated triply-charged ion with the
m/z of 606.28 coeluted with the doubly-charged tryptic
peptide containing Y1173 (m/z of 605.79) (Figure 3b,
Figure 3. Site-specific quantitation of EGFR phosphorylation. (a) LC/MS mass spectrum (spectra
were summed to include phosphorylated and unphosphorylated peptide ions) showing the triply-
charged ions for the unphosphorylated (m/z 800.43) and phosphorylated (m/z 827.09) tryptic peptides
containing Y1086—RPAGSVQNPVYHNQPLNPAPSR. The mass chromatograms for these two ions
are shown in the insert. (b) LC/MS mass spectrum showing the doubly-charged ions for the
unphosphorylated (m/z 605.79) and phosphorylated (m/z 645.79) tryptic peptides containing Y1173—
GSTAENAEYLR. The mass chromatograms for these two ions are shown on the left. (c) LC-MS
spectrum obtained from a mixture of native and 15N-labeled peptide RPAGSVQNPVYHNQPLN-
PAPSR in the phosphorylated and unphosphorylated forms, and the labeled amino acids are
underlined.
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middle). By only using the intensity of the 12C monoiso-
topic peak, ion intensity ratios of the phosphorylated
and unphosphorylated peptide ions containing Y1173
could still be determined. Lower resolution instruments
would not have been able to accurately distinguish the
ion intensity contributions from the two peptides,
thereby compromising the accurate determination of
the ion intensity ratios.
Although changes in ion intensity ratios are indica-
tive of changes in the level of phosphorylation, these
ratios do not directly translate into stoichiometry. Pep-
tide ion intensities vary according to the concentration
of the peptides, suppression effects due to coeluting
material, as well as peptide composition. It is also likely
that addition of phosphate will have an impact on the
ionization efficiency of a peptide [28]. To assess the
effect of the addition of phosphate on ionization, three
pairs of synthetic peptides were synthesized corre-
sponding to the phosphorylated and unphosphorylated
tryptic peptides containing Y1086, Y1148, and Y1173.
Concentrated stock solutions of these synthetic peptides
were made, and their concentrations were determined
by amino acid analysis. From these stock solutions, a
standard was prepared containing equimolar amounts
of the phosphorylated and unphosphorylated peptides,
and this standard mixture of synthetic peptides was
analyzed using the same LC/MS conditions as was
used to acquire data for the EGFR samples. Suprisingly,
for these three pairs of peptides the ion intensity ratios
were close to one—pY1086/Y1086 1.2, pY1148/Y1148
 0.9, and pY1173/Y1173  1.1. This indicated that for
these three phosphorylation sites the ion intensity ratio
of a peptide pair is, to some extent, a realistic assess-
ment of the relative abundance of the peptides. It was
noted, however, that this ratio was sensitive to the
presence of the HPLC ion-pairing reagent HFBA and
very different ratios were obtained in its absence. The
presence of a very small amount of HFBA (0.001%) was
maintained throughout these experiments because of its
beneficial effects on chromatographic resolution and
retention of the more hydrophilic peptides.
Isotope dilution [34] is a standard method for the
quantitation of specific compounds by mass spectro-
metry, and when applied to phosphorylation measure-
ments it is possible to derive absolute quantitation [23].
This approach was feasible for some of the tryptic EGFR
phosphopeptides, and peptides that incorporated 15N-
Val and 15N-Ala were synthesized. The intent is to
verify the quantitative measurements obtained using
the reference peptide method. For example, standards
corresponding to the phosphorylated and unphosphor-
ylated tryptic peptide containing Y1086 (RPAGSVQN-
PVYHNQPLNPAPSR) were synthesized with the 15N
label, which had masses that were 4 u higher than the
corresponding peptides obtained from the naturally
occurring EGFR. By adding known quantities of the
standards into EGFR samples following in-gel diges-
tion, the absolute quantity of the pY1086 and Y1086 in
the sample was determined (Figure 3c). It is recognized
that inefficient extraction of the native peptides from
the gel could result in an underestimation of the abso-
lute quantities; however, assuming that the addition of
phosphate would not affect the efficiency of extraction
out of the gel, the relative molar ratios should be
accurate. Differential losses could occur upon storage of
the in-gel digest sample, but if the standards were
added shortly after digestion, these losses would be
matched by the standards.
Concentration Studies of EGF and TGF Induced
EGFR Phosphorylation
EGF and TGF are homologous proteins that share
similar three-dimensional structures, and are the two
major ligands that activate EGFR. Although these two
ligands exhibit similar biological effects, differences in
downstream biological responses have been reported.
How these two closely related ligands can elicit some-
what different biological signaling is an intriguing
question. Like other ErbB receptor family members,
downstream signaling by EGFR in response to different
ligand stimulation can occur via different mechanisms
[35] — ligand-induction can dictate the formation and
activation of homo- or hetero-dimers, or differential
phosphorylation of the receptor may send different
signals.
To evaluate the contributions of EGFR phosphoryla-
tion on A431 cell ligand-induced downstream signal
transduction, EGFR proteins were immunoprecipitated
following EGF or TGF stimulation of A431 cells using
an antibody that recognizes the extracellular domain of
EGFR. After further separation by gel electrophoresis,
protein bands containing EGFR were cut out, and in-gel
tryptic digestions were performed. For each predicated
phosphorylation site, ion intensity information was
gathered using LC/MS. The ion intensity ratios for each
phosphorylated and unphosphorylated peptide pair
upon ligand stimulation at a wide range of ligand
concentrations were determined (Figure 4). Overall,
EGF (Figure 4a) and TGF (Figure 4b) induction
yielded similar phosphorylation patterns at the differ-
ent sites. A pair of isotope labeled synthetic phosphor-
ylated and unphosphorylated peptides encompassing
Y1086 were available, which were spiked into native
EGF stimulated EGFR tryptic peptide samples. The
results for this one phosphorylation site showed that
the molar ratios measured using isotope dilution were
nearly identical to the ion intensity ratio (data not
shown).
Over a wide range of ligand stimulation (0–1000
ng/ml), all the phosphotyrosine sites showed increased
phosphorylation, but to different degrees. For both
ligands, the extent of Y992 phosphorylation seemed to
plateau at a lower ligand concentration, whereas the
other sites did not seem to reach a maximal level of
phosphorylation even at 1000 ng/ml of ligand. Phos-
phorylation of Y1148 did not seem to occur to any
1028 GUO ET AL. J Am Soc Mass Spectrom 2003, 14, 1022–1031
appreciable extent for either ligand. There was no clear
effect on the phosphorylation of S1142, which is what
would be expected for tyrosine kinase autophosphory-
lation.
Effect of EGFR Inhibitors on Ligand-Induced
Phosphorylation
As shown above, different EGFR sites exhibit differ-
ences in the level of phosphorylation upon stimulation
using varying concentrations of ligand. Our interest in
this was to determine if these changes were of any
relevance in the mechanism of action of EGFR inhibi-
tors. Are there differences in how different sites re-
spond to inhibitor treatment? Are some sites more
sensitive to inhibition than others? To address these
questions, AG1478, a highly potent inhibitor of EGF
receptor kinase [36], was used to treat A431 cells prior
to EGF stimulation. Mass spectrometric analysis of the
EGFR phosphorylation sites indicated that four of the
phosphorylation sites, Y1045, Y1086, Y1148, and Y1173,
are very sensitive to inhibitor treatment, whereas Y992
and Y1068 are still phosphorylated at a significant level
even at the highest concentration of inhibitor (Figure 5).
The inhibitor had no effect on the level of phosphory-
lation of S1142, as expected.
Conclusions
After stimulation with EGF or TGF, LC/MS/MS was
used to show that all of the known tyrosine phosphor-
ylation sites, plus a previously uncharacterized serine
phosphorylation site, were located within five tryptic
peptides generated by in-gel digestion of immunopre-
cipitated EGFR. This formed the basis of an assay for
analyzing the changes in phosphorylation. Changes in
phosphorylation were monitored by comparison of the
ion intensity of phosphopeptides with the unmodified
peptide that was also derived from EGFR. Using this
technique we were able to identify those sites that were
most responsive to stimulation, and compare the site-
specific response obtained using two different ligands
(EGF and TGF). In addition, we were able to monitor
the effects of an EGFR kinase inhibitor on the phosphor-
ylation state of these specific sites. This analysis has
allowed us to investigate more precisely, the mecha-
Figure 4. Ligand-induced changes in EGFR phosphorylation. (a) EGF-induced EGFR phosphoryla-
tion. (b) TGF-induced EGFR phosphorylation. A431 cells were cultured and stimulated with ligands
at the indicated concentrations (see the method section). Data points are the average of three separate
cell treatment samples, and the error bars show the standard deviation.
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nism of action of the EGFR and has wide applications to
similar protein such as other RTKs, cytoplasmic kinases,
and phosphatases. These methods may also be useful in
the clinical arena where extensive efforts are under way
to test the therapeutic potential of drugs that modulate
the enzymatic activity of kinases.
References
1. Carpenter, G. Receptors for Epidermal Growth Factor and
Other Polypeptide Mitogens. Annu. Rev. Biochem. 1987, 56,
881–914.
2. Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The
ErbB Signaling Network: Receptor Heterodimerization in De-
velopment and Cancer. Embo. J. 2000, 19, 3159–3167.
3. Boni-Schnetzler, M.; Pilch, P. F. Mechanism of Epidermal
Growth Factor Receptor Autophosphorylation and High-
Affinity Binding. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7832–
7836.
4. Downward, J.; Parker, P.; Waterfield, M. D. Autophosphory-
lation Sites on the Epidermal Growth Factor Receptor. Nature
1984, 311, 483–485.
5. Hsuan, J. J.; Totty, N.; Waterfield, M. D. Identification of a
Novel Autophosphorylation Site (P4) on the Epidermal
Growth Factor Receptor. Biochem. J. 1989, 262, 659–663.
6. Margolis, B. L.; Lax, I.; Kris, R.; Dombalagian, M.; Honegger,
A. M.; Howk, R.; Givol, D.; Ullrich, A.; Schlessinger, J. All
Autophosphorylation Sites of Epidermal Growth Factor (EGF)
Receptor and HER2/neu are Located in Their Carboxyl-
Terminal Tails. Identification of a Novel Site in EGF Receptor.
J. Biol. Chem. 1989, 264, 10667–10671.
7. Walton, G. M.; Chen, W. S.; Rosenfeld, M. G.; Gill, G. N.
Analysis of Deletions of the Carboxyl Terminus of the Epider-
mal Growth Factor Receptor Reveals Self-Phosphorylation at
Tyrosine 992 and Enhanced in Vivo Tyrosine Phosphorylation
of Cell Substrates. J. Biol. Chem. 1990, 265, 1750–1754.
8. Levkowitz, G.; Waterman, H.; Ettenberg, S. A.; Katz, M.;
Tsygankov, A. Y.; Alroy, I.; Lavi, S.; Iwai, K.; Reiss, Y.;
Ciechanover, A.; Lipkowitz, S.; Yarden, Y. Ubiquitin Ligase
Activity and Tyrosine Phosphorylation Underlie Suppression
of Growth Factor Signaling by c-Cbl/Sli-1. Mol. Cell 1999, 4,
1029–1040.
9. Shoelson, S. E. SH2 and PTB Domain Interactions in Tyrosine
Kinase Signal Transduction. Curr. Opin. Chem. Biol. 1997, 1,
227–234.
10. Herbst, R. S.; Shin, D. M. Monoclonal Antibodies to Target
Epidermal Growth Factor Receptor-Positive Tumors: A New
Paradigm for Cancer Therapy. Cancer 2002, 94, 1593–1611.
11. Couzin, J. Cancer Drugs. Smart Weapons Prove Tough to
Design. Science 2002, 298, 522–525.
12. Campbell, D.; Morrice, N. Identification of Protein Phosphor-
ylation Sites by a Combination of Mass Spectrometry and
Solid Phase Edman Sequencing. J. Biomol. Tech. 2002, 13,
119–130.
13. Fenn, J. B.; Mann, M.; Meng, C. K.; Wong, S. F.; Whitehouse,
C. M. Electrospray Ionization for Mass Spectrometry of Large
Biomolecules. Science 1989, 246, 64–71.
14. Karas, M.; Hillenkamp, F. Laser Desorption Ionization of
Proteins with Molecular Masses Exceeding 10,000 Daltons.
Anal. Chem. 1988, 60, 2299–2301.
15. Ficarro, S. B.; McCleland, M. L.; Stukenberg, P. T.; Burke, D. J.;
Ross, M. M.; Shabanowitz, J.; Hunt, D. F.; White, F. M.
Phosphoproteome Analysis by Mass Spectrometry and Its
Application to Saccharomyces cerevisiae. Nat. Biotechnol. 2002,
20, 301–305.
16. Oda, Y.; Nagasu, T.; Chait, B. T. Enrichment Analysis of
Phosphorylated Proteins as a Tool for Probing the Phospho-
proteome. Nat. Biotechnol. 2001, 19, 379–382.
17. Zhou, H.; Watts, J. D.; Aebersold, R. A Systematic Approach to
the Analysis of Protein Phosphorylation. Nat. Biotechnol. 2001,
19, 375–378.
18. Zhang, X.; Herring, C. J.; Romano, P. R.; Szczepanowska, J.;
Brzeska, H.; Hinnebusch, A. G.; Qin, J. Identification of
Phosphorylation Sites in Proteins Separated by Polyacryl-
amide Gel Electrophoresis. Anal. Chem. 1998, 70, 2050–2059.
19. Ma, Y.; Lu, Y.; Zeng, H.; Ron, D.; Mo, W.; Neubert, T. A.
Characterization of Phosphopeptides from Protein Digests
Using Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry and Nanoelectrospray Quadrupole
Time-of-Flight Mass Spectrometry. Rapid Commun. Mass Spec-
trom. 2001, 15, 1693–1700.
Figure 5. Effects of EGFR kinase inhibitor AG1478 on EGF-induced EGFR phosphorylations. The
A431 cells were treated with the inhibitor for 20 min prior to the addition of 100 ng/ml EGF.
1030 GUO ET AL. J Am Soc Mass Spectrom 2003, 14, 1022–1031
20. Zappacosta, F.; Huddleston, M. J.; Karcher, R. L.; Gelfand,
V. I.; Carr, S. A.; Annan, R. S. Improved Sensitivity for
Phosphopeptide Mapping Using Capillary Column HPLC and
Microionspray Mass Spectrometry: Comparative Phosphory-
lation Site Mapping from Gel-Derived Proteins. Anal. Chem.
2002, 74, 3221–3231.
21. Steen, H.; Kuster, B.; Fernandez, M.; Pandey, A.; Mann, M.
Detection of Tyrosine Phosphorylated Peptides by Precursor
Ion Scanning Quadrupole TOF Mass Spectrometry in Positive
Ion Mode. Anal. Chem. 2001, 73, 1440–1448.
22. MacCoss, M. J.; McDonald, W. H.; Saraf, A.; Sadygov, R.;
Clark, J. M.; Tasto, J. J.; Gould, K. L.; Wolters, D.; Washburn,
M.; Weiss, A.; Clark, J. I.; Yates, J. R., III. Shotgun Identification
of Protein Modifications from Protein Complexes and Lens
Tissue. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7900–7905.
23. Stemmann, O.; Zou, H.; Gerber, S. A.; Gygi, S. P.; Kirschner,
M. W. Dual Inhibition of Sister Chromatid Separation at
Metaphase. Cell 2001, 107, 715–726.
24. Oda, Y.; Huang, K.; Cross, F. R.; Cowburn, D.; Chait, B. T.
Accurate Quantitation of Protein Expression and Site-Specific
Phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6591–
6596.
25. Tsay, Y. G.; Wang, Y. H.; Chiu, C. M.; Shen, B. J.; Lee, S. C. A
Strategy for Identification and Quantitation of Phosphopep-
tides by Liquid Chromatography/Tandem Mass Spectro-
metry. Anal. Biochem. 2000, 287, 55–64.
26. Asara, J. Lane, W. Ratio Analyzed Quantitation (RAQ) of
Phosphorylation Sites from Different Protein States by LC/
MS/MS. Proceedings of the 50th Conference on Mass Spectrometry
and Allied Topics; Orlando, FL, 2002.
27. Ruse, C. I.; Willard, B.; Jin, J. P.; Haas, T.; Kinter, M.; Bond, M.
Quantitative Dynamics of Site-Specific Protein Phosphoryla-
tion Determined Using Liquid Chromatography Electrospray
Ionization Mass Spectrometry. Anal. Chem. 2002, 74, 1658–
1664.
28. Lee, K. A.; Craven, K. B.; Niemi, G. A.; Hurley, J. B. Mass
Spectrometric Analysis of the Kinetics of in Vivo Rhodopsin
Phosphorylation. Protein Sci 2002, 11, 862–874.
29. Wrann, M. M.; Fox, C. F. Identification of Epidermal Growth
Factor Receptors in a Hyperproducing Human Epidermoid
Carcinoma Cell Line. J. Biol. Chem. 1979, 254, 8083–8086.
30. Giard, D. J.; Aaronson, S. A.; Todaro, G. J.; Arnstein, P.;
Kersey, J. H.; Dosik, H.; Parks, W. P. In Vitro Cultivation of
Human Tumors: Establishment of Cell Lines Derived from a
Series of Solid Tumors. J. Natl. Cancer Inst. 1973, 51, 1417–1423.
31. Perkins, D. N.; Pappin, D. J.; Creasy, D. M.; Cottrell, J. S.
Probability-Based Protein Identification by Searching Se-
quence Databases. Electrophoresis 1999, 20, 3551–3567.
32. Spahr, C.; Susin, S.; Bures, E.; Robinson, J.; Davis, M.; McGin-
ley, M.; Kroemer, G.; Patterson, S. Simplification of Complex
Peptide Mixtures for Proteomic Analysis: Reversible Biotiny-
lation of Cysteinyl Peptides. Electrophoresis 2000, 21, 1635–
1650.
33. Wu, D. G.; Wang, L. H.; Sato, G. H.; West, K. A.; Harris, W. R.;
Crabb, J. W.; Sato, J. D. Human Epidermal Growth Factor
(EGF) Receptor Sequence Recognized by EGF Competitive
Monoclonal Antibodies. Evidence for the Localization of the
EGF-Binding Site. J. Biol. Chem. 1989, 264, 17469–17475.
34. Chapman, J. R. Practical Organic Mass Spectrometry; John
Wiley and Sons, Ltd.: West Sussex, 1993; pp. 272–305.
35. Sweeney, C; Carraway, K. L., III. Ligand Discrimination by
ErbB Receptors: Differential Signaling Through Differential
Phosphorylation Site Usage. Oncogene 2000, 19, 5568–5573.
36. Gazit, A.; Chen, J.; App, H.; McMahon, G.; Hirth, P.; Chen, I.;
Levitzki, A. Tyrphostins IV—Highly Potent Inhibitors of EGF
Receptor Kinase. Structure-Activity Relationship Study of
4-Anilidoquinazolines. Bioorg. Med. Chem. 1996, 4, 1203–1207.
37. Biemann, K. Appendix V. Nomenclature for Peptide Fragment
Ions (Positive Ions). Methods Enzymol 1990, 193, 886–887.
1031J Am Soc Mass Spectrom 2003, 14, 1022–1031 PHOSPHORYLATION OF EGFR
